Regulatory briefing
LATEST ALERTS
-
Luxembourg Bill to legalise cannabis plant cultivation expected in June… - Delaware - United States Recreational cannabis bill fails to pass…
- United States Califf says congressional action needed for CBD…
- United States First federal appeals court rules on the legality of delta-8 products…
- Germany Government to set cannabis possession limit…
- Colombia New forum to be held to provide information on cannabis legislation…
- Guyana Hemp bill presented to National Assembly…
- Thailand Cannabis growth without approval from June…
- New Zealand Three new medical cannabis products are approved…
- Europe EU to update hazardous substances list…
- Europe Stakeholder event on tobacco taxation in the EU held today…
- New York - United States Senate passes bill relating to business development and promotion of hemp…
THC lookalike products lead packaged goods group to campaign for tougher law
Written by Lorraine Mullaney || 19th May 2022 || Regulatory briefing |
A small change in proposed legislation could make it significantly easier to prevent the sale of “lookalike” cannabis products that work off existing well-known trademarks ...
Belize cannabis and hemp legalisation bill faces opposition, late referendum
Written by CBD-Intel || 17th May 2022 || Regulatory briefing |
The fate of a recently approved cannabis and industrial hemp bill in Belize is likely to be decided by a national referendum after opposition groups submitted a petition in early May in an effort to block cannabis legalisation in the Central American...
EU officially recognises first CBG-rich hemp variety among registered plants
Written by Tiziana Cauli || 13th May 2022 || Regulatory briefing |
The EU has granted official recognition to a hemp variety rich in cannabigerol (CBG) by including a new cannabinoid strain in its database of registered plant varieties ...
Pennsylvania medical cannabis vape recall leaves patients stranded
Written by CBD-Intel || 13th May 2022 || Regulatory briefing |
A widespread recall of cannabis concentrates sold for vaping at medical cannabis dispensaries in the US state of Pennsylvania has left patients with more questions than answers about who to trust ...
Argentina approves law to establish legal framework for cannabis and hemp
Written by CBD-Intel || 13th May 2022 || Regulatory briefing |
Members of the Argentina Chamber of Deputies approved a law on 5th May that would establish a legal framework for the production, sale and export of medical cannabis as well as industrial hemp, a decision president Alberto Fernández...
How likely is it that the US will see further delta-8 THC enforcement?
Written by Freddie Dawson || 12th May 2022 || Blog , Regulatory briefing |
The US Food and Drug Administration (FDA) recently sent its first round of letters concerning delta-8 THC to five companies. How likely is it that the US will see further delta-8 THC enforcement? ...
Europe seeks makeover for rules on CBD in cosmetics in wake of Kanavape ruling
Written by Sergi Riudalbàs Clemente || 9th May 2022 || Regulatory briefing |
A non-paper is being drafted by European authorities to examine how to change rules to formally permit the use of CBD in cosmetics in Europe following the Courts of Justice of the European Union (CJEU) decision in the...
Basel moves forward with its recreational cannabis trial
Written by CBD-Intel || 6th May 2022 || Regulatory briefing |
Basel will start allowing the sale of recreational cannabis through local pharmacies at the end of the summer as the first Swiss city to win the approval of health authorities for the pilot project ...
US FDA sets its sights on delta-8 THC, firing warnings over health claims
Written by Anthony Traurig || 5th May 2022 || Regulatory briefing |
The US Food and Drug Administration (FDA) has sent warning letters to five marketers of delta-8 THC products over health claims made by the companies ...
Update nearly doubles the length of UK FSA’s novel food applications list
Written by Freddie Dawson || 5th May 2022 || Regulatory briefing |
The list of products linked to novel food applications in the UK has nearly doubled in length with the addition of 2,446 products by the Foods Standards Agency (FSA) ...
Kanavape ruling: 17 months on, EU-wide compliance remains patchy and unsure
Written by Sergi Riudalbàs Clemente || 4th May 2022 || Regulatory briefing |
The European Commission has emphasised once again that EU member states must apply the ruling of the Courts of Justice of the European Union (CJEU) in the Kanavape decision to national law ...
DEA defines cannabis seeds with less than 0.3% THC as hemp and as legal
Written by Tiziana Cauli || 2nd May 2022 || Regulatory briefing |
The US Drug Enforcement Administration (DEA) has confirmed that cannabis seeds fall outside the realm of the Controlled Substances Act (CSA) – regardless of how much THC the plant could eventually yield ...
Different strokes for different folks – why the EU’s not all one for wellness CBD
Written by Lorraine Mullaney || 26th April 2022 || Regulatory briefing |
Companies selling CBD wellness products in the EU must be wary of the lack of harmonisation at the EU level and the potential complications this can bring ...
Polish court decision on hemp as novel food could have big ramifications
Written by Freddie Dawson || 14th April 2022 || Blog , Regulatory briefing |
A Polish appeals court has put forward a decision that may be out of kilter with many other interpretations of the status of hemp as a novel food ...
Appeals court hands hemp company a victory in Polish ‘novel food’ battle
Written by CBD-Intel || 14th April 2022 || Regulatory briefing |
A Polish appeals court has accepted arguments that hemp was consumed before 1997, making it non-novel and leading the court to overturn a decision by the country’s Chief Sanitary Inspectorate ...
Argentine bill to establish legal cannabis industry set to be passed ‘within weeks’
Written by CBD-Intel || 14th April 2022 || Regulatory briefing |
Argentina’s Chamber of Deputies is expected to approve a bill creating a legal framework for the cultivation, manufacture and sale of medicinal cannabis and hemp “within two months”, CBD-Intel has been told ...
EIHA gives warm welcome to EU-wide THC limits, but uncertainties remain
Written by CBD-Intel || 13th April 2022 || Regulatory briefing |
Maximum THC levels for hempseed foods and oil across the EU are a major step forward in clarifying the regulation of hemp-derived products, according to the European Industrial Hemp Association (EIHA) ...
Canada’s cannabis industry welcomes a federal budget full of good things
Written by CBD-Intel || 11th April 2022 || Regulatory briefing |
Canada’s cannabis trade is celebrating after the government tabled a budget calling for steps to streamline a variety of tax measures and launch a strategy group to examine ways to grow the industry ...
So far so good, but German lawmakers urged to go further on medical cannabis
Written by CBD-Intel || 11th April 2022 || Regulatory briefing |
Five years after German patients were first allowed to obtain medical cannabis, demand has risen sharply – but there are still some unanswered issues on policy and practice that lobbyists want addressed ...
Morocco authorises cannabis growth for medical purposes in three regions
Written by CBD-Intel || 8th April 2022 || Regulatory briefing |
The Cabinet of the Moroccan government has formally adopted the decision to authorise three regionsto lawfully grow cannabis solely for medical purposes ...
Argentina’s president and development minister back cannabis framework
Written by CBD-Intel || 7th April 2022 || Regulatory briefing |
Argentina’s president is urging the national Congress to approve a law this year that would establish a legal framework for the production and sale of medicinal cannabis and industrial hemp ...
Long trips for a short supply, but there’s optimism in Iowa on medical cannabis
Written by CBD-Intel || 6th April 2022 || Regulatory briefing |
Patients in Iowa who rely on supplies of medical cannabis are tightly restricted in how much they can have, and may face a long trip to get it from one of the few licensed dispensaries in the US...
US FDA warns CBD firms over fraudulent and ‘life-threatening’ Covid claims
Written by Tiziana Cauli || 5th April 2022 || Regulatory briefing |
The US Food and Drug Administration (FDA) has issued warning letters to seven CBD companies for claiming that some of the products they sell may be used to prevent or cure Covid-19 ...
People vs politics – Wisconsin remains divided over what to do about cannabis
Written by CBD-Intel || 4th April 2022 || Regulatory briefing |
Lawmakers in the US state of Wisconsin are sympathetic to patients who could benefit from medical cannabis – but they don’t want to go against federal law ...
Through a glass darkly – CHUMP aims to spread a little post-Brexit light on CBD
Written by CBD-Intel || 1st April 2022 || Regulatory briefing |
UK authorities moved today (1st April) to give new clarity on the legal status of CBD and other cannabinoids, with a new department ready to clear up Home Office mess ...
Canada’s proposed changes could open up non-therapeutic cannabis research
Written by CBD-Intel || 31st March 2022 || Regulatory briefing |
The Canadian government is proposing changes to make it easier to conduct non-therapeutic cannabis research in the country and to foster more investigation into the development of cannabis products ...
UK FSA finally publishes long-rumoured list of validated novel food applications
Written by Antonia di Lorenzo || 31st March 2022 || Regulatory briefing |
The UK Food Standards Agency (FSA) has published a list of around 3,500 CBD food products whose applications for novel food status have been validated or still await validation ...
Colombia at the forefront with two-tier THC limits for hemp plant parts
Written by Laura Garay Gómez || 31st March 2022 || Regulatory briefing |
A two-tier THC limit providing more leniency for the production of flowers is the latest addition to Colombia’s strong cannabinoid regulatory foundations ...
Disappointment across US after CBD language dropped from omnibus bill
Written by CBD-Intel || 29th March 2022 || Regulatory briefing |
CBD stakeholders hoping for clarity in US regulations were left disappointed by the passing of the $1.5tn omnibus spending bill earlier this month as some helpful language was dropped during the final negotiations ...
Are there lessons for cannabinoids from the new synthetic-nicotine regulation?
Written by Freddie Dawson || 24th March 2022 || Blog , Regulatory briefing |
Could the cannabinoid industry learn anything from the recent move to close the loophole that had kept synthetic nicotine out of US Food and Drug Administration oversight? ...
European Commission moving ahead slowly on permissible THC levels in food
Written by CBD-Intel || 24th March 2022 || Regulatory briefing |
THC levels have been established for certain hemp foodstuffs, which may later govern the amount of THC allowed in ingestible cannabinoid products, experts working for the European Commission have confirmed ...
Canada ready to raise the legal limit on purchases of cannabis-infused drinks
Written by CBD-Intel || 22nd March 2022 || Regulatory briefing |
The Canadian government is proposing a change in the regulations governing cannabis-infused beverages to increase the number of drinks that can legally be bought at a time ...
Poland set to grow cannabis for medical use after Senate ratifies hemp bill
Written by CBD-Intel || 15th March 2022 || Regulatory briefing |
The Polish Senate has passed a bill introducing new regulations on hemp growing and medical cannabis with minimal changes from the version already approved by the lower parliamentary chamber, the Sejm ...
South Dakota in the US passes legislation making delta-8 THC legal for adult use
Written by CBD-Intel || 14th March 2022 || Regulatory briefing |
South Dakota’s Republican governor, Kristi Noem, has signed House Bill (HB) 1292, legalising the sale of delta-8 THC, THC-O acetate, and hexahydrocannabinol (HHC) in the state after the bill flew through the state legislature almost unanimously ...
Costa Rica legalises medicinal cannabis as well as commercial hemp production
Written by CBD-Intel || 8th March 2022 || Regulatory briefing |
Costa Rican president Carlos Alvarado ratified a bill on 2nd March that legalises the sale and distribution of medicinal cannabis and allows for the commercial production of hemp in the Central American nation ...
Virginia bill could pose significant threat to CBD products in the state
Written by Anthony Traurig || 3rd March 2022 || Regulatory briefing |
A bill originally aimed at restricting the shapes that edible cannabis products may take has morphed into a potential significant threat to CBD products in Virginia ...
NORML releases delta-8 THC info that’s both misleading and potentially divisive
Written by Freddie Dawson || 3rd March 2022 || Blog , Regulatory briefing |
One of the most prestigious cannabis legalisation lobbying groups has come out with a disappointing – but not surprising – strong line against hemp-derived delta-8 THC products ...
Italian Constitutional Court rejects referendum on decriminalising cannabis
Written by CBD-Intel || 25th February 2022 || Regulatory briefing |
An Italian referendum on the potential decriminalisation of cannabis for personal use has been rejected by the country’s Constitutional Court ...
Mississippi medical cannabis bill finally becomes law
Written by CBD-Intel || 25th February 2022 || Regulatory briefing |
Mississippi has finally signed a medical cannabis bill into law after a long and often arduous...
SAFE amendment to America COMPETES Act unlikely to be part of final bill proposal
Written by CBD-Intel || 22nd February 2022 || Regulatory briefing |
The SAFE Banking Act, which sets out to protect banks from being penalised for providing services to legitimate cannabis-related businesses, is on shaky ground ...
Thailand relaxes the rules on cannabis, removing whole plant from narcotics list
Written by CBD-Intel || 21st February 2022 || Regulatory briefing |
Thailand has removed the entire cannabis plant including flowers and seeds from the country’s list of Category 5 narcotics ...
South American legislation on cannabis and hemp will progress, if slowly, in 2022
Written by CBD-Intel || 8th February 2022 || Regulatory briefing |
This is an important year for positive legislation affecting cannabinoids across South America, though some depends on election results and all of it will take a few years to take effect ...
Costa Rica’s president promises to get cannabis legalisation done despite veto
Written by CBD-Intel || 7th February 2022 || Regulatory briefing |
Costa Rican president Carlos Alvarado, who has supported the legalisation of cannabis throughout his administration, has partially vetoed a bill that would have legalised medicinal cannabis and industrial hemp ...
Export expert outlines post-Brexit tips for moving goods into the UK or Europe
Written by Lorraine Mullaney || 2nd February 2022 || Regulatory briefing |
Andy Hooper, CEO of Global E-Commerce Experts, provides tips for companies wishing to export into Europe. He'll expand on this in a talk at White Label World Expo in London on 2nd and 3rd March ...
Will UK FSA at last publish an updated list of validated novel food applications?
Written by Freddie Dawson || 2nd February 2022 || Blog , Regulatory briefing |
Don't hold your breath, but rumours are swirling that the UK Food Standards Agency (FSA) will soon publish an updated, completed list of CBD novel food applications that have been fully validated ...
Ambiguity and misinformation on Italian hemp decree spread yet more confusion
Written by CBD-Intel || 28th January 2022 || Regulatory briefing |
A recent agreement to update the Italian list of officinal (medically usable) plants has caused some unfounded consternation in the country’s CBD industry ...
French government defeated in court as hemp flower sales ban is suspended
Written by CBD-Intel || 27th January 2022 || Regulatory briefing |
France’s highest administrative court has temporarily and partially suspended the French decree banning the sale and consumption of CBD hemp flowers ...
US lawsuits end DEA restrictions on sources of cannabis for researchers
Written by CBD-Intel || 26th January 2022 || Regulatory briefing |
Lawsuits in the US have finally overturned the DEA's requirement that researchers interested in studying cannabis could only purchase from one source, the University of Mississippi ...